Zeng Yanbin, Lin Wanlong, Zhuang Wei
Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.
J Neurol. 2025 May 28;272(6):429. doi: 10.1007/s00415-025-13172-3.
Many women are exposed to antiseizure medications (ASMs) during pregnancy, raising concerns about pregnancy and offspring health risks. The current safety data remain insufficient, necessitating further investigation.
Using data from the FDA Adverse Event Reporting System (2010-2023), this study employed both the Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) for disproportionality analysis of pregnancy and offspring toxicity related to maternal ASM exposure. In addition, we performed signal adjustment by excluding polytherapy cases, and drug-drug interaction (DDI) signals of two ASMs were identified using Ω Shrinkage measures and Chi-square tests.
3,459 mothers were exposed to 23 ASMs, resulting in 10,910 adverse events. 59 malformation signals, 27 adverse perinatal outcome signals, and 35 dysplasia signals were identified. Among traditional ASMs, valproic acid (VPA) and carbamazepine (CBZ) exhibited the highest number of signals, while levetiracetam (LEV), lamotrigine (LTG), lacosamide, gabapentin, and topiramate (TPM) predominated among newer ASMs. Signals for cardiac malformations, adverse neurodevelopment, and adverse offspring growth outcomes were widespread, with the strongest signals for specific outcomes observed for zonisamide [ROR = 14.82, 95% CI: 5.43-40.41], gabapentin [ROR = 52.52, 95% CI: 15.68-175.95], and brivaracetam [ROR = 22.96, 95% CI: 8.42-62.61], respectively. Six DDI signals displayed ≥ 3, including LTG + LEV/VPA associated with malformation, CBZ + lacosamide/LTG, and VPA + clonazepam associated with fetal loss.
The potential risks associated with LEV and LTG surpass expectations, warranting further evaluation, particularly in combination therapy. In addition, ASMs with widespread signals, such as VPA, CBZ, TPM, and lacosamide, warrant heightened attention.
许多女性在孕期会接触抗癫痫药物(ASMs),这引发了对妊娠及后代健康风险的担忧。目前的安全数据仍然不足,需要进一步调查。
利用美国食品药品监督管理局不良事件报告系统(2010 - 2023年)的数据,本研究采用报告比值比(ROR)和贝叶斯置信传播神经网络(BCPNN)对与母亲ASM暴露相关的妊娠和后代毒性进行不成比例分析。此外,我们通过排除联合治疗病例进行信号调整,并使用Ω收缩测量法和卡方检验识别两种ASM的药物 - 药物相互作用(DDI)信号。
3459名母亲接触了23种ASMs,导致10910起不良事件。识别出59个畸形信号、27个围产期不良结局信号和35个发育异常信号。在传统ASMs中,丙戊酸(VPA)和卡马西平(CBZ)的信号数量最多,而在新型ASMs中,左乙拉西坦(LEV)、拉莫三嗪(LTG)、拉科酰胺、加巴喷丁和托吡酯(TPM)占主导地位。心脏畸形、不良神经发育和后代生长不良结局的信号广泛存在,唑尼沙胺[ROR = 14.82,95%CI:5.43 - 40.41]、加巴喷丁[ROR = 52.52,95%CI:15.68 - 175.95]和布瓦西坦[ROR = 22.96,95%CI:8.42 - 62.61]分别观察到特定结局的最强信号。六个DDI信号显示≥3,包括与畸形相关的LTG + LEV/VPA、CBZ + 拉科酰胺/LTG以及与胎儿丢失相关的VPA + 氯硝西泮。
与LEV和LTG相关的潜在风险超出预期,需要进一步评估,特别是在联合治疗中。此外,具有广泛信号的ASMs,如VPA、CBZ、TPM和拉科酰胺,需要高度关注。